{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:06:21Z","timestamp":1694736381529},"reference-count":45,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.jad.2010.09.010","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T09:01:57Z","timestamp":1286182917000},"page":"205-212","source":"Crossref","is-referenced-by-count":3,"title":["No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C"],"prefix":"10.1016","volume":"129","author":[{"given":"Ziad","family":"Kronfol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Litman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Back-Madruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linas A.","family":"Bieliauskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna S.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Supp 2","key":"10.1016\/j.jad.2010.09.010_bb0005","article-title":"Colchicine versus peg-interferon alfa 2B long term therapy: results of the 4year copilot trial","volume":"48","author":"Afdhal","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jad.2010.09.010_bb0010","series-title":"BDI-II Manual","author":"Beck","year":"1996"},{"key":"10.1016\/j.jad.2010.09.010_bb0015","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jhep.2005.01.024","article-title":"Interferon-\u03b1-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression","volume":"42","author":"Cai","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jad.2010.09.010_bb0020","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1056\/NEJM199904293401716","article-title":"Prediction of the depressive effects of interferon alfa therapy by the patients initial affective state [letter]","volume":"340","author":"Capuron","year":"1999","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.jad.2010.09.010_bb0025","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0006-3223(03)00173-2","article-title":"Interferon-alpha-induced changes in tryptophan metabolism relationship to depression and paroxetine treatment","volume":"54","author":"Capuron","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0030","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1176\/appi.ajp.160.7.1342","article-title":"Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy","volume":"10","author":"Capuron","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0168-8278(03)00189-2","article-title":"Quality of life and cognitive function in hepatitis C at different stages of liver disease","volume":"39","author":"Cordoba","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jad.2010.09.010_bb0040","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1210\/jc.81.9.3265","article-title":"Endocrine and metabolic effects of interferon-\u03b1 in humans","volume":"81","author":"Corsmit","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jad.2010.09.010_bb0045","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon","volume":"359","author":"Di Bisceglie","year":"2008","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.jad.2010.09.010_bb0050","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","article-title":"Neuropsychiatric symptoms associated with hepatitis C and interferon \u03b1: a review","volume":"157","author":"Dieperink","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0055","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1176\/appi.psy.44.2.104","article-title":"A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C","volume":"44","author":"Dieperink","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jad.2010.09.010_bb0060","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000097211","article-title":"Cytokine effects on CNS biogenic amines","volume":"2","author":"Dunn","year":"1995","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.jad.2010.09.010_bb0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage IIII melanoma: final results of EORTC 18991, a randomized phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2010.09.010_bb0075","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1038\/ajg.2009.528","article-title":"Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the ViraHep-C study","volume":"104","author":"Evon","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jad.2010.09.010_bb0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4088\/JCP.v63n0213c","article-title":"Interferon-induced depression treated with citalopram","volume":"63","author":"Farah","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0085","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cgh.2006.10.016","article-title":"Effect of prolonged interferon therapy on the outcome of hepatitis C virus related cirrhosis: a randomized trial","volume":"5","author":"Fartoux","year":"2007","journal-title":"Clin. Gasteroenterol. Hepatol."},{"key":"10.1016\/j.jad.2010.09.010_bb0225","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2005.04.006","article-title":"Cognitive function in Hepatitis C patients with advanced fibrosis in the HALT-C Trial","volume":"43","author":"Fontana","year":"2005","journal-title":"J. Hepatology"},{"key":"10.1016\/j.jad.2010.09.010_bb0090","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1111\/j.1572-0241.2008.02106.x","article-title":"Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C","volume":"103","author":"Fontana","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jad.2010.09.010_bb0095","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/ajg.2010.3","article-title":"Cognitive function does not worsen during long-term low dose peginterferon therapy in patients with chronic hepatitis C","volume":"105","author":"Fontana","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jad.2010.09.010_bb0100","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0016-5085(03)00394-9","article-title":"Side effects of antiviral therapy for hepatitis C","volume":"124","author":"Fried","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jad.2010.09.010_bb0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4088\/JCP.v63n0304","article-title":"An open label trial of citalopram for major depression in patients with hepatitis C","volume":"63","author":"Gleason","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0110","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.mp.4001119","article-title":"A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C","volume":"9","author":"Hauser","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0115","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1017\/S1355617703960048","article-title":"Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C","volume":"9","author":"Hilsabeck","year":"2003","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.jad.2010.09.010_bb0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1176\/appi.ajp.157.5.683","article-title":"Cytokines and the brain: implications for clinical psychiatry","volume":"157","author":"Kronfol","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0125","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cct.2004.08.003","article-title":"Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders","volume":"25","author":"Lee","year":"2004","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.jad.2010.09.010_bb0130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2036.2006.02748.x","article-title":"Treating chronic hepatitis C with pegylated interferon alfa-2a (40kD) and ribavirin in clinical practice","volume":"23","author":"Lee","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2010.09.010_bb0135","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa-1","volume":"20","author":"Mahon","year":"2002","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.jad.2010.09.010_bb0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000026485","article-title":"Interferon alpha induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha","volume":"37","author":"Malaguarnera","year":"1998","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jad.2010.09.010_bb0145","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.biopsych.2008.11.029","article-title":"Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression","volume":"65","author":"Miller","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0150","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1176\/appi.psy.47.2.93","article-title":"Hepatitis C treatment for people with severe mental illness","volume":"47","author":"Mistler","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jad.2010.09.010_bb0155","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.jad.2010.09.010_bb0160","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the esophagus for bleeding esophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.jad.2010.09.010_bb0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of interferon-\u03b1: recognition and management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2010.09.010_bb0170","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1126\/science.2821621","article-title":"Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor","volume":"238","author":"Sapolsky","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.jad.2010.09.010_bb0175","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0278-5846(01)00324-4","article-title":"Interferon alpha (IFNalpha) and psychiatric syndromes: a review","volume":"26","author":"Schaefer","year":"2002","journal-title":"Prog. Neuropsychoparmacol. Biol. Psychiatry"},{"issue":"4 Suppl. 1","key":"10.1016\/j.jad.2010.09.010_bb0180","doi-asserted-by":"crossref","first-page":"320A","DOI":"10.1016\/S0270-9139(03)80376-2","article-title":"Citalopram for the prevention of interferon-\u03b1 associated depression in psychiatric risk patients","volume":"38","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jad.2010.09.010_bb0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jhep.2009.10.007","article-title":"Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression","volume":"52","author":"Sch\u00e4fer","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jad.2010.09.010_bb0190","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gasteroenterology"},{"key":"10.1016\/j.jad.2010.09.010_bb0195","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1176\/ajp.142.9.1017","article-title":"Overview: toward a dysregulation hypothesis of depression","volume":"142","author":"Siever","year":"1985","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0200","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.15288\/jsa.1982.43.1157","article-title":"Reliability of alcohol use indices: the lifetime drinking history and the MAST","volume":"43","author":"Skinner","year":"1982","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.jad.2010.09.010_bb0205","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2036.2010.04235.x","article-title":"Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C","volume":"31","author":"Snow","year":"2010","journal-title":"Aliment. Pharm. Ther."},{"key":"10.1016\/j.jad.2010.09.010_bb0210","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.mp.4001600","article-title":"IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity","volume":"10","author":"Wichers","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2010.09.010_bb0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-3956(94)90036-1","article-title":"Reliability and validity studies of the WHO Composite International Diagnostic Interview: a critical review","volume":"28","author":"Wittchen","year":"1994","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2010.09.010_bb0220","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/brbi.2000.0597","article-title":"The relationship of depression and stressors to immunological assays: a meta-analytic review","volume":"15","author":"Zorrilla","year":"2001","journal-title":"Brain Behav. Immun."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032710005781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032710005781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T16:51:01Z","timestamp":1544201461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032710005781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":45,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0165032710005781"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2010.09.010","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}